Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen‐treated women
Authors:
Open Access
Abstract
BACKGROUND: Ultrasonography has a limited value in endometrial assessment for identification of endometrial pathologies in postmenopausal tamoxifen‐treated patients.METHODS: We compared the rate of endometrial pathologies and the mean ± SD of endometrial thickness diagnosed after the first and second transvaginal ultrasonographic studies performed on 55 postmenopausal tamoxifen‐treated patients with secondary endometrial thickening (Group I). This rate was also compared with 46 similar patients without secondary thickening (Group II). We also compared the mean ± SD of endometrial thickness detected in various ultrasonographic studies, as well as various clinical features.RESULTS: A significantly higher rate of endometrial pathologies, including two cases of endometrial cancer identified in gynecologically asymptomatic patients (3.6%), was diagnosed in Group I after the second study compared with the first study (52.7% and 9.1%, respectively; P = 0.001) and compared with those diagnosed after the second study in Group II (30.4%; P = 0.03). There was a significant increase (74.7 ± 115%) in endometrial thickness after the second study compared with the first study performed on Group I (10.7 ± 5.53 mm and 16.59 ± 5.53 mm, respectively; P = 0.0001) and a significant difference in endometrial thickness demonstrated in the second study performed on Groups I and II (16.59 ± 5.53 mm and 11.4 ± 3.91 mm, respectively; P = 0.001).There were no significant differences in the time elapsed since the diagnosis of breast carcinoma and from the beginning of tamoxifen treatment to the performance of the first ultrasonographic study as well as the time elapsed between the first and second studies performed.CONCLUSIONS: A significant increase (> 50%) in secondary endometrial thickening, measured ultrasonographically, in postmenopausal tamoxifen‐treated patients, is associated with a high rate of endometrial pathologies, including endometrial cancer. Cancer 2002;94:3101–6. © 2002 American Cancer Society.DOI 10.1002/cncr.10587Keywords
This publication has 27 references indexed in Scilit:
- Long-Term Transvaginal Ultrasonographic Endometrial Follow-up in Postmenopausal Breast Cancer Patients with Tamoxifen TreatmentGynecologic Oncology, 1999
- Transvaginal endometrial sonography in postmenopausal women taking tamoxifenObstetrics & Gynecology, 1999
- The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifenUltrasound in Obstetrics & Gynecology, 1998
- Value of Sonohysterography in Asymptomatic Postmenopausal Tamoxifen-Treated PatientsGynecologic Oncology, 1997
- Screening by Ultrasonography for Endometrial Carcinoma in Postmenopausal Breast Cancer Patients under Adjuvant TamoxifenGynecologic Oncology, 1996
- Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological studyUltrasound in Obstetrics & Gynecology, 1995
- Unusual ultrasonographic appearance of uterus in postmenopausal patients receiving tamoxifenAmerican Journal of Obstetrics and Gynecology, 1995
- Ultrasonography surveillance of endometrium in breast cancer patients on adjuvant tamoxifenThe Lancet, 1994
- Endometrial Changes with Tamoxifen: Comparison between Tamoxifen-Treated and Nontreated Asymptomatic, Postmenopausal Breast Cancer PatientsGynecologic Oncology, 1994
- The effects of tamoxifen on the endometriumUltrasound in Obstetrics & Gynecology, 1994